Specifically, loss-of-function of PTPN2 sensitized B16 cells to immunotherapy in vivo and increased the sensitivity to T cell immunity in a Braf/Pten melanoma model, without affecting cell viability and growth in the absence of T cells. The gene discussed is PTPN2; the disease is melanoma.